Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It contains only transaction-specific data:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.6373 per share.
- Transaction Volume: 31 shares.
- Transaction Date: July 14, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of shares by a Person Discharging Managerial Responsibilities (PDMR) following the re-investment of dividends paid on July 14, 2016, under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a share acquisition.
Investor Verification Points
- Verify the identity of the PDMR: Dr. P J T Vallance, President, Pharmaceuticals R&D.
- Confirm the transaction nature: Acquisition via dividend re-investment under the ShareReward Plan.
- Note the transaction size: 31 shares, indicating a routine plan-based transaction rather than a significant open-market purchase.